Tom Carroll retweeted
Building @numenbio with @_tom_dot_com to engineer a future without cancer deaths. Find out more below in an interview with our partners at @TQVentures!
A cancer test that runs inside a cup. Taken at home, with results sent to your doctor in 30 minutes. Built in a San Francisco lab by a team that started in a shipping container.
What it actually takes to build it:
“If we spend ten, 20, 30, 40 years working on this, that’s okay. The outcome will be worth it.”
@luca_springer, co-founder and CEO of @numenbio
Timestamps:
00:00 Welcome to Numen
00:56 Why catch cancer early
01:24 The first lab was a shipping container
02:28 What the data unlocks next
03:23 National team MVP to founder
04:13 Why bladder cancer first
05:33 The candle prototype
06:25 Meet Atlas, a lab in a cup
06:55 NASA engineers under one roof
07:32 The Viennese café
08:08 Pipette pong
08:46 From the dungeon to Golden Gate Park
09:28 The only milestone that matters
09:59 40 years on one problem
Proud to be building @numenbio with @luca_springer and with great backers like @TQVentures in our corner!
A cancer test that runs inside a cup. Taken at home, with results sent to your doctor in 30 minutes. Built in a San Francisco lab by a team that started in a shipping container.
What it actually takes to build it:
“If we spend ten, 20, 30, 40 years working on this, that’s okay. The outcome will be worth it.”
@luca_springer, co-founder and CEO of @numenbio
Timestamps:
00:00 Welcome to Numen
00:56 Why catch cancer early
01:24 The first lab was a shipping container
02:28 What the data unlocks next
03:23 National team MVP to founder
04:13 Why bladder cancer first
05:33 The candle prototype
06:25 Meet Atlas, a lab in a cup
06:55 NASA engineers under one roof
07:32 The Viennese café
08:08 Pipette pong
08:46 From the dungeon to Golden Gate Park
09:28 The only milestone that matters
09:59 40 years on one problem
Tom Carroll retweeted
A cancer test that runs inside a cup. Taken at home, with results sent to your doctor in 30 minutes. Built in a San Francisco lab by a team that started in a shipping container.
What it actually takes to build it:
“If we spend ten, 20, 30, 40 years working on this, that’s okay. The outcome will be worth it.”
@luca_springer, co-founder and CEO of @numenbio
Timestamps:
00:00 Welcome to Numen
00:56 Why catch cancer early
01:24 The first lab was a shipping container
02:28 What the data unlocks next
03:23 National team MVP to founder
04:13 Why bladder cancer first
05:33 The candle prototype
06:25 Meet Atlas, a lab in a cup
06:55 NASA engineers under one roof
07:32 The Viennese café
08:08 Pipette pong
08:46 From the dungeon to Golden Gate Park
09:28 The only milestone that matters
09:59 40 years on one problem
We’ve been building quietly at @numenbio for the past few years. Tomorrow we’re sharing more for the first time, in a conversation with Schuster at @TQVentures.
Here’s a teaser; full interview tomorrow.
Inside the lab engineering a future without cancer deaths.
Tomorrow: @numenbio with @luca_springer.
Inside the lab engineering a future without cancer deaths
Numen is engineering a future without cancer deaths. This is the second episode of House Calls, a Bourdain-style documentary series filmed in the places that shape how founders build.
Tom Carroll retweeted
Operable setting (2026): sciencedirect.com/science/ar…
Inoperable setting (2023): cell.com/cancer-cell/fulltex…
In this new work, we also establish a 5-gene signature C-FISH correlated with TMC to allow estimation of this parameter when bulk RNA-seq is not available. Happy reading!
Tom Carroll retweeted
🚨 New paper out: Tumor monocyte content predicts immunochemotherapy outcomes for operable esophageal cancer. Similar to our previous work in inoperable setting, high TMC is associated w/ longer OS. May help identify EAC patients likely to respond to neoadjuvant ICI. Links below:
🚨 New paper out: Tumor monocyte content predicts immunochemotherapy outcomes for operable esophageal cancer. Similar to our previous work in inoperable setting, high TMC is associated w/ longer OS. May help identify EAC patients likely to respond to neoadjuvant ICI. Links below:
Operable setting (2026): sciencedirect.com/science/ar…
Inoperable setting (2023): cell.com/cancer-cell/fulltex…
In this new work, we also establish a 5-gene signature C-FISH correlated with TMC to allow estimation of this parameter when bulk RNA-seq is not available. Happy reading!
Tom Carroll retweeted
The reason mRNA can't cure more diseases? Delivery.
We built NGX1 to deliver mRNA to any cell in the body using AI and multivalent physics.
Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEYNOTE-B15/EV-304 trial results: nej.md/4wh8FB9
Editorial: A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era? nej.md/4b67lZi

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer." The graph shows event-free survival. The trial name, KEYNOTE-B15/EV-304, is in parentheses after the title. The NEJM identity sits at the bottom.
Tom Carroll retweeted
Truly monumental day for the #Ross community. Congratulations to trailblazers and colleagues @IHamamsy and @OuzounianMD for simultaneous publication of their incredible manuscripts reaffirming the magic of the Ross Procedure in @JACCJournals
Tom Carroll retweeted
🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!
AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
ir.revmed.com/news-releases/…
Tom Carroll retweeted
For the second year in a row, Parafilm has been recognized with the Nobel Prize in Chemistry 2025! 🏅



















